

Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation


Alan Van Goethem^{1,2}, Jill Deleu^{1,2}, Nurten Yigit^{1,2}, Celine Everaert^{1,2}, Myrthala Moreno-Smith³, Sanjeev A. Vasudevan³, Fjoralba Zeka^{1,2}, Fleur Demuyne^{1,2}, Eveline Barbieri³, Frank Speleman^{2,4}, Pieter Mestdagh^{1,2}, Jason Shohet⁵, Jo Vandesompele^{1,2,6} and Tom Van Maerken^{1,2,6}

[†]shared contributions


¹OncoRNALab, Cancer Research Institute Ghent (CRIG), Ghent, Belgium, ²Department of Biomolecular Medicine, Ghent University, Ghent, Belgium, ³Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA, ⁴PPOL, Cancer Research Institute Ghent (CRIG), Ghent, Belgium, ⁵Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of Massachusetts Chan Medical School, Worcester, MA, USA and ⁶Department of Laboratory Medicine, AZ Groeninge, Kortrijk, Belgium

✉ Jill.Deleu@UGent.be


miRNAs to monitor tumor burden?




miRNAs to monitor treatment responses?



serum miRNA abundance recapitulates tumor burden




miR-34a-5p as a pharmacodynamic biomarker for idasanutlin treatment in serum and tumor tissue



higher abundance of tumor-derived miRNAs in serum of human neuroblastoma patients

HR-NB: high-risk neuroblastoma H: healthy control S: sarcoma N: nephroblastoma R: rhabdomyosarcoma



future perspectives

